First-line treatment of acute lymphoblastic leukemia with pegasparaginase

References

• ApostolidouESwordsRAlvaradoYTreatment of acute lymphoblastic leukaemia: a new eraDrugs200767152153217117927282
   PubMed Web of Science ®Google Scholar
• PuiCHEvansWETreatment of acute lymphoblastic leukemiaN Engl J Med2006354216617816407512
   PubMed Web of Science ®Google Scholar
• GökbugetNHoelzerDTreatment of adult acute lymphoblastic leukemiaSemin Hematol2009461647519100369
   PubMed Web of Science ®Google Scholar
• OrtegaJANesbitMEJrDonaldsonMHl-Asparaginase, vincristine and prednisone for induction of first remission in acute lymphoblastic leukemiaCancer Res1977372535540264412
   PubMed Web of Science ®Google Scholar
• JonesBHollandJFGlidewellOOptimal use of l-asparaginase (NSC-109229) in acute lymphoblastic leukemiaMed Pediatr Oncol197734387400337095
   PubMedGoogle Scholar
• ClavellLAGelberRDCohenHJFour-agent induction and intensive l-asparaginase therapy for treatment of childhood acute lymphoblastic leukemiaN Engl J Med1986315116576632943992
   PubMed Web of Science ®Google Scholar
• SchrappeMReiterALudwigWImproved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines cranial radiotherapy: results of trial ALL-BFM 90Blood200095113310332210828010
   PubMed Web of Science ®Google Scholar
• HannIVoraARichardsSBenefit of intensified treatment for all children with acute lymphoblastic leukemia: results from MRC UKALL XI and MRC ALL97 randomized trialsLeukemia200014335636310720126
   PubMed Web of Science ®Google Scholar
• KiddJGRegression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serumJ Exp Med195398656558213109110
   PubMed Web of Science ®Google Scholar
• KiddJGRegression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussionJ Exp Med195398658360613109111
   PubMed Web of Science ®Google Scholar
• MashburnLTWristonJCJrTumor inhibitory effect of L-asparaginase from Escherichia coliArch Biochem Biophys196410545045214186753
   PubMed Web of Science ®Google Scholar
• PessionAValsecchiMGMaseraGLong-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemiaJ Clin Oncol200523287161716716192600
   PubMed Web of Science ®Google Scholar
• NartaUKKanwarSSAzmiWPharmacological and clinical evaluation of L-asparaginase in the treatment of leukemiaCrit Rev Oncol Hematol200761320822117011787
   PubMed Web of Science ®Google Scholar
• ErtelIJNesbitMEHammondDEffective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study GroupCancer Res1979391038933896383278
   PubMed Web of Science ®Google Scholar
• NesbitMChardREvansAEvaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemiaAm J Pediatr Hematol Oncol197911913295576
   PubMedGoogle Scholar
• RizzariCCitterioMZucchettiMA pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemiaHaematologica2006911243116434367
   PubMed Web of Science ®Google Scholar
• AbuchowskiAVan EsTPalczukNCTreatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginaseCancer Treat Rep197963611271132466651
   PubMedGoogle Scholar
• YoshimotoTNishimuraHSaitoYCharacterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemiaJpn J Cancer Res19867712126412703102431
   PubMedGoogle Scholar
• VeroneseFMMeroAThe impact of PEGylation on biological therapiesBio Drugs2008225315329
   Google Scholar
• DuvalMSuciuSFersterAComparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trialBlood20029982734273911929760
   PubMed Web of Science ®Google Scholar
• CampbellHAMashburnLTBoyseEATwo L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activityBiochemistry1967637217305337885
   PubMed Web of Science ®Google Scholar
• JacksonRCHandschumacherREEscherichia coli L-asparaginase. Catalytic activity and subunit natureBiochemistry1970918358535904928351
   PubMed Web of Science ®Google Scholar
• MaitaTMatsudaGThe primary structure of L-asparaginase from Escherichia coliHoppe Seylers Z Physiol Chem198036121051176766894
   PubMedGoogle Scholar
• WhelanHAWristonJCJrPurification and properties of asparaginase from escherichia coli BBiochemistry196986238623934895020
   PubMed Web of Science ®Google Scholar
• ChabnerBALooTLChabnerBALongoDLEnzyme therapy: L-asparaginaseCancer Chemotherapy and Biotherapy PrinciplesPhiladelphiaLippincot-Raven1966485492
   Google Scholar
• SwainALJaskólskiMHoussetDCrystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapyProc Natl Acad Sci U S A1993904147414788434007
   PubMed Web of Science ®Google Scholar
• MolineuxGPegylation: engineering improved pharmaceuticals for enhanced therapyCancer Treat Rev200228 Suppl A131612173407
   PubMed Web of Science ®Google Scholar
• AbuchowskiAKazoGMVerhoestCRJrCancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugatesCancer Biochem Biophys1984721751866467175
   PubMedGoogle Scholar
• KamisakiYWadaHYaguraTReduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycolJ Pharmacol Exp Ther198121624104147007618
   PubMed Web of Science ®Google Scholar
• WadaHImamuraISakoMAntitumor enzyme: polyethylene glycol-modified asparaginaseAnn N Y Acad Sci1990613951082076022
   PubMed Web of Science ®Google Scholar
• KeatingMJHolmesRLernerSL-asparaginase and PEG asparaginase – past, present, and futureLeuk Lymphoma199310 Suppl1531578481665
   PubMedGoogle Scholar
• FuCHSakamotoKMPEG-ASNase araginaseExpert Opin Pharmacother20078121977198417696798
   PubMed Web of Science ®Google Scholar
• EttingerLJKurtzbergJVoûtePAAn open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemiaCancer1995755117611817850718
   PubMed Web of Science ®Google Scholar
• Vieira PinheiroJPWennerKEscherichGSerum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97Pediatr Blood Cancer2006461182515929133
   PubMed Web of Science ®Google Scholar
• HakLJRellingMVChengCAsparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemiaLeukemia20041861072107715057247
   PubMed Web of Science ®Google Scholar
• MüllerHJBeierRda PalmaJCPEG-ASNase araginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocolsCancer Chemother Pharmacol200249214915411862429
   PubMed Web of Science ®Google Scholar
• KiriyamaYKubotaMTakimotoTBiochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetaseLeukemia1989342942972564453
   PubMed Web of Science ®Google Scholar
• PragerMDBachynskyNAsparagine synthetase in asparaginase resistant and susceptible mouse lymphomasArch Biochem Biophys196812716456544880551
   PubMed Web of Science ®Google Scholar
• HaskellCMCanellosGPCooneyDABiocmical and pharmacologic effects of L-asparaginase in manJ Lab Clin Med19707557637704909251
   PubMed Web of Science ®Google Scholar
• CooneyDAHandschumacherREL-asparaginase and L-asparagine metabolismAnnu Rev Pharmacol1970104214404911021
   PubMedGoogle Scholar
• CapizziRLBertinoJRSkeelRTL-asparaginase: clinical, biochemical, pharmacological, and immunological studiesAnn Intern Med19717468939015281051
   PubMed Web of Science ®Google Scholar
• AsselinBLRyanDFrantzCNIn vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginaseCancer Res19894915436343682743326
   PubMed Web of Science ®Google Scholar
• UenoTOhtawaKMitsuiKCell cycle arrest and apoptosis of leukemia cells induced by L-asparaginaseLeukemia199711111858185619369418
   PubMed Web of Science ®Google Scholar
• ShimizuTKubotaMAdachiSPre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etopo-side-induced DNA strand breakage and cytotoxicityInt J Cancer19925046446481537631
   PubMed Web of Science ®Google Scholar
• CapizziRLAggarwalKFisherJWAsparaginaseBiochemical Pharmacology of Blood and Blood Forming AgentsHeidelbergSpringer1992548565
   Google Scholar
• ParkYKAbuchowskiADavisSPharmacology of Escherichia coli-L-asparaginase polyethylene glycol adductAnticancer Res1981163733767046623
   PubMed Web of Science ®Google Scholar
• BergSLBalisFMMcCullyCLPharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkeyCancer Chemother Pharmacol19933243103148324873
   PubMed Web of Science ®Google Scholar
• AvramisVISencerSPericlouAPA randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group studyBlood2002996198694 Erratum in Blood. 2002; 100(5):153111877270
   PubMed Web of Science ®Google Scholar
• HoDHBrownNSYenAClinical pharmacology of polyethylene glycol-L-asparaginaseDrug Metab Dispos19861433493522872037
   PubMed Web of Science ®Google Scholar
• AsselinBLWhitinJCCoppolaDJComparative pharmacokinetic studies of three asparaginase preparationsClin Oncol199311917801786
   Web of Science ®Google Scholar
• HolleLMPegaspargase: an alternative?Ann Pharmacother19973156166249161659
   PubMed Web of Science ®Google Scholar
• AlbertsenBKJakobsenPSchrøderHPharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administrationCancer Chemother Pharmacol2001481778211488528
   PubMed Web of Science ®Google Scholar
• DouerDYampolskyHCohenLJPharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemiaBlood200710972744275017132721
   PubMed Web of Science ®Google Scholar
• WennerKAVieira PinheiroJPEscherichGAsparagine concentration in plasma after 2,500 IU/m2 PEG-ASNase araginase i.v. in children with acute lymphoblastic leukemiaKlin Padiatr2005217632132616307417
   PubMed Web of Science ®Google Scholar
• CapizziRLAsparaginase revisitedLeuk Lymphoma199310 Suppl1471508481663
   PubMedGoogle Scholar
• PanosyanEHSeibelNLMartin-AragonSAsparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961J Pediatr Hematol Oncol200426421722615087948
   PubMed Web of Science ®Google Scholar
• OhnumaTHollandJFFreemanABiochemical and pharmacological studies with asparaginase in manCancer Res1970309229723054920133
   PubMed Web of Science ®Google Scholar
• CheungNKChauIYCocciaPFAntibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurementAm J Pediatr Hematol Oncol198682991043526939
   PubMedGoogle Scholar
• AppelIMPinheiroJPden BoerMLLack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-ASNase araginase: a window study at initial diagnosis of childhood ALLLeukemia200317112254225614523472
   PubMed Web of Science ®Google Scholar
• DinndorfPAGootenbergJCohenMHFDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)Oncologist200712899199817766659
   PubMed Web of Science ®Google Scholar
• AvramisVIPanosyanEHPharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the futureClin Pharmacokinet200544436739315828851
   PubMed Web of Science ®Google Scholar
• WetzlerMSanfordBLKurtzbergJEffective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511Blood2007109104164416717264295
   PubMed Web of Science ®Google Scholar
• ArmstrongJKHempelGKolingSAntibody against poly(ethylene glycol) adversely affects PEG-ASNase araginase therapy in acute lymphoblastic leukemia patientsCancer2007110110311117516438
   PubMed Web of Science ®Google Scholar
• HakLJRellingMVChengCAsparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemiaLeukemia20041861072107715057247
   PubMed Web of Science ®Google Scholar
• HaskellCMCanellosGPl-asparaginase resistance in human leukemia–asparagine synthetaseBiochem Pharmacol19691810257825804935103
   PubMed Web of Science ®Google Scholar
• BroomeJDSchwartzJHDifferences in the production of L-asparagine in asparaginase-sensitive and resistant lymphoma cellsBiochim Biophys Acta196713836376396036864
   PubMed Web of Science ®Google Scholar
• PragerMDBachynskyNAsparagine synthetase in asparaginase resistant and susceptible mouse lymphomasBiochem Biophys Res Commun196831143474869945
   PubMed Web of Science ®Google Scholar
• KiriyamaYKubotaMTakimotoTBiochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetaseLeukemia1989342942972564453
   PubMed Web of Science ®Google Scholar
• HutsonRGKitohTMoraga AmadorDAAmino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cellsAm J Physiol19972725 Pt 1C1691C16999176161
   PubMed Web of Science ®Google Scholar
• GallagherMPMarshallRDWilsonRAsparaginase as a drug for treatment of acute lymphoblastic leukaemiaEssays Biochem1989241402676522
   PubMedGoogle Scholar
• HollemanAden BoerMLKazemierKMResistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemiaBlood2003102134541454612920041
   PubMed Web of Science ®Google Scholar
• FaderlSThallPFKantarjianHMCaspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemiaClin Cancer Res19995124041404710632337
   PubMed Web of Science ®Google Scholar
• GallagherMPMarshallRDWilsonRl-Asparaginase a drug for treatment of acute lymphoblastic leukemiaEssays Biochem1989241402676522
   PubMedGoogle Scholar
• HaskellCMCanellosGPLeventhalBGL-asparaginase: therapeutic and toxic effects in patients with neoplastic diseaseN Engl J Med196928119102810344898857
   PubMed Web of Science ®Google Scholar
• Package InsertOncaspar (pegaspargase)Rhone-Pooulenc RorerCollegeville, PA1994
   Google Scholar
• OettgenHFTallalLTanCCGrundmanEOettegenHFExperimental and clinical effects of l-asparaginaseClinical Experience with L-asparaginaseNew YorkSpringer197021943
   Google Scholar
• AndersonNLokichJJTullisJLL-asparaginase effect on antithrombin-III levelsMed Pediatr Oncol197974335340296786
   PubMedGoogle Scholar
• PriestJRRamsayNKCBennetAJThe effect of l-asparaginase on antithrombin, plasminogen and plasma coagulation during therapy for acute lymphoblastic leukemiaJ Pediatr198210069909956953222
   PubMed Web of Science ®Google Scholar
• HomansACRybakMEBagliniRLEffect of l-asparaginase administration on coagulation and platelet function in children with leukemiaJ Clin Oncol1987558118173572467
   PubMed Web of Science ®Google Scholar
• GugliottaLD’AngeloAMattioli-BelmonteMHypercoagulability during l-asparaginase treatment: the effect of antithrombin III supplementation in vivioBr J Hematol1990744465470
   PubMed Web of Science ®Google Scholar
• WermesCvon Depka ProndzinskiMLichtinghagenRClinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous cathetersEur J Pediatr1999158 Suppl 3S143S14610650855
   PubMed Web of Science ®Google Scholar
• KnoflerRSiegertELauterbachIClinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous linesEur J Pediatr1999158 Suppl 3S147S15010650856
   PubMed Web of Science ®Google Scholar
• Mauz-KörholzCJunkerRGöbelUProthrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols)Thromb Haemost200083684084310896235
   PubMed Web of Science ®Google Scholar
• NguyenDLWilsonDAEnglemanEDSerial sonogram to detect pancreatitis in children receiving l-asparaginaseSouth Med J1987809113311363306944
   PubMed Web of Science ®Google Scholar
• SamuelsBICulbertSJOkamuraJEarly detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography: a preliminary reportCancer197638415151523991074
   PubMed Web of Science ®Google Scholar
• PochedlyCNeurotoxicity due to CNS therapy for leukemiaMed Pediatr Oncol197731101115840159
   PubMedGoogle Scholar
• Vieira PinheiroJPMüllerHJSchwabeDDrug monitoring of low-dose PEG-ASNase araginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemiaBr J Haematol2001113111511911328290
   PubMed Web of Science ®Google Scholar
• TaylorCWDorrRTFantaPA phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumorsCancer Chemother Pharmacol2001471838811221967
   PubMed Web of Science ®Google Scholar
• AguayoACortesJThomasDCombination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemiaCancer19998671203120910506705
   PubMed Web of Science ®Google Scholar
• DouerDCohenLJPeridouLAPeg-L-asparaginase (PEG-ASNASE): Pharmacokinetics (PK) and clinical response in newly diagnosed adults with acute lymphoblastic leukemia (ALL) treated with multiagent chemotherapyBlood199790Suppl 1334a
   Google Scholar
• MussHBSpellNScudieryDA phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphomaInvest New Drugs1990811251302345067
   PubMed Web of Science ®Google Scholar
• SilvermanLBGelberRDDaltonVKImproved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood20019751211121811222362
   PubMed Web of Science ®Google Scholar
• RosenOMüllerHJGökbugetNPegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot studyBr J Haematol2003123583684114632774
   PubMed Web of Science ®Google Scholar
• HolcenbergJSencerSCohenLJRandomised trial of PEG vs native l-asparaginase in children with newly diagnosed acute lymphoblastic leukemia (ALL): CCG study 1962Blood199994628a
   Web of Science ®Google Scholar
• AbshireTCPollockBHBillettALWeekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group StudyBlood20009651709171510961868
   PubMed Web of Science ®Google Scholar
• AppelIMKazemierKMBoosJPharmacokinetic, pharmacodynamic and intracellular effects of PEG-ASNase araginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window studyLeukemia20082291665167918580955
   PubMed Web of Science ®Google Scholar
• ZeidanAWangESWetzlerMPegasparaginase: where do we stand?Expert Opin Biol Ther20099111111919063697
   PubMed Web of Science ®Google Scholar
• WooMHHakLJStormMCHypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemiaJ Clin Oncol20001871525153210735901
   PubMed Web of Science ®Google Scholar
• van der EijkAAVrolijkJMHaagmansBLAntibodies neutralizing peginterferon alfa during retreatment of hepatitis CN Engl J Med2006354121323132416554542
   PubMed Web of Science ®Google Scholar
• PetersBGGoecknerBJPonzilloJJPegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessmentFormulary199530738839310151730
   PubMedGoogle Scholar
• KurreHAEttingerAGVeenstraDLA pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children’s Cancer Group study (CCG-1962)J Pediatr Hematol Oncol200224317518111990302
   PubMed Web of Science ®Google Scholar